We are live on !
Find out more
Braidwell Portfolio holdings
AUM
$2.7B
Turnover
43.12%
1-Year Est. Return
88.53%
Braidwell is a healthcare-focused investment firm that runs hedge funds and a private equity fund to build and back companies fighting disease. It was started in 2021 by Alex Karnal, its chief investment officer and a former co-portfolio manager at Deerfield Management, and Brian Kreiter, its chief executive and a former chief operating officer of Bridgewater Associates. They set it up to combine scientific research with systematic, technology-driven investing.
This Fund
S&P 500
This Quarter Est. Return
+4.66%
1 Year Est. Return
+88.53%
3 Year Est. Return
+96.53%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.98B
AUM Growth
–
Cap. Flow
+$1.68B
Cap. Flow % of AUM
Cap. Flow %
56.29%
Top 10 Holdings %
Top 10 Hldgs %
33.01%
Holding
88
New
63
Increased
–
Reduced
–
Closed
–
Avg Time Held
0
years
Top 10 Avg Time Held
0
years
Top 20 Avg Time Held
0
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Glaukos
GKOS
|
+$82M |
| 2 |
Biogen
BIIB
|
+$71.3M |
| 3 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
+$71.3M |
| 4 |
Natera
NTRA
|
+$66.8M |
| 5 |
Crinetics Pharmaceuticals
CRNX
|
+$61.1M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 56.69% |
| 2 | Miscellaneous | 43.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
Glaukos
GKOS
$13B
| $72.6M | 2.43% |
+1,661,851
| New | +$82M |
2022 Q4
0 quarters
|
|
|
ISEE
2
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $71.5M | 2.4% |
+3,341,300
| New | +$71.3M |
2022 Q4
0 quarters
|
|
|
3
Biogen
BIIB
$36.1B
| $69.9M | 2.34% |
+252,542
| New | +$71.3M |
2022 Q4
0 quarters
|
|
4
Vaxcyte
PCVX
$9.8B
| $65.3M | 2.19% |
+1,362,278
| New | +$53.5M |
2022 Q4
0 quarters
|
|
|
5
Natera
NTRA
$52.4B
| $65.1M | 2.18% |
+1,621,012
| New | +$66.8M |
2022 Q4
0 quarters
|
|
|
6
DELISTED
Crinetics Pharmaceuticals
CRNX
| $63.5M | 2.13% |
+3,469,674
| New | +$61.1M |
2022 Q4
0 quarters
|
|
7
Xenon Pharmaceuticals
XENE
$3.65B
| $61M | 2.05% |
+1,548,110
| New | +$56.4M |
2022 Q4
0 quarters
|
|
8
Intuitive Surgical
ISRG
$166B
| $59.2M | 1.98% |
+223,120
| New | +$54.4M |
2022 Q4
0 quarters
|
|
9
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $53.6M | 1.8% |
+3,271,513
| New | +$53.2M |
2022 Q4
0 quarters
|
|
10
DELISTED
NEVRO CORP.
NVRO
| $47.2M | 1.58% |
+1,192,298
| New | +$49.6M |
2022 Q4
0 quarters
|
|
11
iRhythm Holdings
IRTC
$4.29B
| $46.6M | 1.56% |
+497,667
| New | +$54.2M |
2022 Q4
0 quarters
|
|
12
Align Technology
ALGN
$11.2B
| $46.4M | 1.55% |
+219,930
| New | +$44M |
2022 Q4
0 quarters
|
|
13
Outset Medical
OM
$77.4M
| $44M | 1.47% |
+113,637
| New | +$32M |
2022 Q4
0 quarters
|
|
14
OrthoPediatrics
KIDS
$841M
| $41.5M | 1.39% |
+1,044,699
| New | +$43.5M |
2022 Q4
0 quarters
|
|
15
Aclaris Therapeutics
ACRS
$559M
| $37.7M | 1.26% |
+2,393,985
| New | +$38.5M |
2022 Q4
0 quarters
|
|
16
Penumbra
PEN
$12.7B
| $36.2M | 1.21% |
+162,828
| New | +$31.8M |
2022 Q4
0 quarters
|
|
17
Amgen
AMGN
$249B
| $34.4M | 1.15% |
+131,100
| New | +$35.1M |
2022 Q4
0 quarters
|
|
|
BLU
18
DELISTED
BELLUS Health Inc.
BLU
| $33.8M | 1.13% |
+4,112,494
| New | +$38.3M |
2022 Q4
0 quarters
|
|
19
Legend Biotech
LEGN
$4.38B
| $32.9M | 1.1% |
+658,101
| New | +$31.9M |
2022 Q4
0 quarters
|
|
20
Syndax Pharmaceuticals
SNDX
$844M
| $31.6M | 1.06% |
+1,242,802
| New | +$29M |
2022 Q4
0 quarters
|
|
21
DELISTED
Merus
MRUS
| $30.9M | 1.04% |
+1,998,084
| New | +$35.2M |
2022 Q4
0 quarters
|
|
22
Travere Therapeutics
TVTX
$4.69B
| $30.6M | 1.03% |
+1,455,585
| New | +$30.8M |
2022 Q4
0 quarters
|
|
23
Krystal Biotech
KRYS
$8.9B
| $28.4M | 0.95% |
+358,056
| New | +$26.6M |
2022 Q4
0 quarters
|
|
24
DELISTED
HilleVax
HLVX
| $27.1M | 0.91% |
+1,620,216
| New | +$29.3M |
2022 Q4
0 quarters
|
|
25
DELISTED
Day One Biopharmaceuticals
DAWN
| $26.8M | 0.9% |
+1,246,539
| New | +$25.6M |
2022 Q4
0 quarters
|
|
Similar funds
Braidwell's Q4 2022 Portfolio in Review
Q4 2022 is the first quarter with a 13F filing on record for Braidwell, which disclosed 88 positions worth $2.98B. Its ten largest holdings account for 33% of the portfolio.
Its largest position is Glaukos: 1,661,851 shares worth $72.6M.
By sector, the portfolio is most concentrated in Healthcare at 57% of assets, followed by Miscellaneous.
- Braidwell's largest Q4 2022 buy was Glaukos: 1,661,851 shares worth $72.6M.
- Braidwell's ten largest holdings make up 33% of its $2.98B portfolio in Q4 2022.
- Braidwell disclosed 88 positions in Q4 2022, its first 13F filing on record.
Based on Braidwell's 13F filing for Q4 2022, filed 14 Feb 2023.